In the phase 3 trial from the European Organisation for Research and Treatment of Cancer published by Hegi et al., there was a 46% 2 year survival for those patients who had epigenetic silencing via methylation of the promoter of the gene which metabolises Temozolomide (O-6-methylguanine-DNA-methyltransferase, MGMT) [4]. This evidence concerns the gene MGMT and cancer.